CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.

Lopes-Pacheco M. · 2019

Read CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. by Lopes-Pacheco M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7046560.txt.

Description

Lopes-Pacheco reviews CFTR modulator drugs in Frontiers in Pharmacology, writing as sole author. Cystic fibrosis is a lethal inherited disease caused by mutations in the CFTR gene, found in 1989. Faulty CFTR protein impairs the lungs above all, and lung disease drives most deaths. Better symptom care has lengthened lives, but quality of life stays limited.

Modulators attack the root defect instead of symptoms. They can restore function to specific mutant proteins, and they fall into five groups by action: potentiators, correctors, stabilizers, read-through agents, and amplifiers. Cell-based screening sped their discovery. Four modulators had reached the market when the review was written, with short- and long-term gains changing patients' lives. The author frames them as precision medicine: matching the drug to the mutation each patient carries.

Catalog record

CREATORLopes-Pacheco M.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE162 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7046560

Browse the full library · About the Tower of Babel